SEC 8-K filings, classified by Claude with reasoning. Ingested in near-real time from EDGAR's filing stream, reconciled overnight.
Material 8-K events ordered by the time EDGAR accepted them. New filings appear at the top automatically — no refresh needed. Only filings ingested in near-real-time appear here; the daily-index reconciliation backstop fills in the catalog overnight, but those rows don't carry a sub-day timestamp and land on the Latest view instead.
Richard Morrissy resigned from the Company's Board of Directors effective immediately on June 14, 2026, due to health concerns limiting his ability to serve. This is a clear director departure disclosure under Item 5.02, and board composition changes are material to investors assessing governance and continuity.
View raw filing on EDGAR →ProtoKinetix appointed three individuals as directors on June 17, 2026, with Keith Brunt also appointed as president of the Company. Brunt's elevation to president represents a material executive role change, with extensive biographical detail provided on his qualifications.
View raw filing on EDGAR →ProtoKinetix formed a subsidiary (SightPath Biotech LLC) to develop PKX-001 for dry-eye disease with patents valued at approximately $253 million, disclosed late filings of its 2025 10-K and 2026 Q1 10-Q, and repriced 61.19 million options and 6 million warrants downward from $0.028 to $0.01 per share with extended expiration dates. The combination of subsidiary formation with substantial IP valuation, filing delays, and significant dilutive equity repricing reflects material corporate restructuring and financial stress.
View raw filing on EDGAR →The filing discloses cancellation of 7.1 million pre-funded warrants pending a legal investigation into suspected misconduct including collusion, beneficial ownership cap violations, use of foreign nominees, and transfer agent discrepancies. While this involves warrant cancellation and regulatory/legal concerns, it does not fit neatly into the specific categories (not a litigation disclosure per se, not a covenant breach, not a delisting notice). The material nature of the investigation and warrant cancellation warrants classification as a material event outside the standard taxonomy.
View raw filing on EDGAR →Acrivon held its Annual Meeting of Stockholders and disclosed voting results for three proposals: election of two Class I directors (Michael Tomsicek and Charles Baum), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the Amended and Restated 2022 Equity Incentive Plan. All three proposals passed with substantial majorities.
View raw filing on EDGAR →The filing discloses a "strategic investment in Skyline Instruments Corporation" announced via press release on June 17, 2026. While the prose does not specify the investment amount, structure, or whether it constitutes a material acquisition under Item 1.01, a strategic investment by a public company is typically material to investors assessing the registrant's capital allocation and business strategy. The disclosure does not fit the more specific categories (ma_activity would require clearer language about acquisition/merger/change of control; dilutive_issuance would require equity issuance detail). Classified as other_material pending fuller details in the attached exhibit.
View raw filing on EDGAR →The Company extended the expiration date of a rights offering from June 23 to June 29, 2026, at a subscription price of $6.90 per share. While this is a material capital-raising event affecting shareholder dilution and the Company's financing timeline, it does not fit neatly into the more specific categories (dilutive_issuance typically covers the initial announcement of an unregistered equity sale, not an extension of an existing offering). The extension itself is material to investors tracking the offering's progress and their subscription decision window.
View raw filing on EDGAR →The disclosure announces a 1-for-20 reverse share split effective July 1, 2026, for the 2x Long VIX Futures ETF (UVIX). While reverse splits are structural corporate actions that affect share price and outstanding share count, this event does not fit neatly into the delisting_risk category (no delisting threat is mentioned) nor any other specific taxonomy category. The action is material to shareholders as it affects NAV per share, share count, and potential tax consequences from fractional share redemptions, warranting classification as other_material.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the Company's 2026 Annual Meeting of Stockholders held on June 16, 2026. The filing reports final voting tallies for two proposals: (1) election of two Class I directors (Daniel Nelson and Hongfei Zhang, both elected with overwhelming support), and (2) ratification of Carr, Riggs & Ingram, L.L.C. as independent auditor (ratified with 27,782,849 votes for). This is a textbook Item 5.07 disclosure with specific vote counts and outcomes.
View raw filing on EDGAR →The filing discloses completion of a material acquisition on June 17, 2026, whereby Rumble Inc. acquired approximately 85.2% of Northern Data AG through an exchange offer and direct purchases from transaction support agreement sellers. Item 2.01 explicitly states "Completion of Acquisition or Disposition of Assets" and describes the issuance of 16.6 million shares to public shareholders and 42.8 million shares plus pre-funded warrants to TSA Sellers as consideration. This is a transformative business combination involving a substantial equity issuance and acquisition of a controlling stake in a foreign corporation.
View raw filing on EDGAR →The disclosure centers on the Compensation Committee's approval of equity awards (1,961,986 PSUs and 783,618 RSUs) granted to executive officers including the CEO, CFO, and Chief Accounting Officer under the 2026 Equity Incentive Plan. This is a classic compensatory arrangement disclosure under Item 5.02(e), with specific vesting schedules and performance targets tied to stock price appreciation over three years. The awards represent 37% of authorized shares and are material to investor assessment of executive compensation.
View raw filing on EDGAR →The filing discloses a merger transaction between Sila Realty Trust and Sunshine Ultimate Parent LLC, with a special stockholder meeting scheduled for June 26, 2026 to approve the merger. The Item 8.01 disclosure supplements the proxy statement with updated financial advisor analyses and background information regarding the merger process, including contact with 81 potential buyers. This is a material acquisition/change of control event that would significantly affect investor assessment of the registrant.
View raw filing on EDGAR →Bed Bath & Beyond entered into a Merger Agreement and Plan of Reorganization with Fathom Holdings Inc. on June 16, 2026, whereby Fathom will merge with a wholly owned subsidiary of the Company, with Fathom surviving as a subsidiary of Bed Bath & Beyond. This is a material acquisition involving an exchange ratio of 0.2236 shares of Company Common Stock per FTHM share, subject to customary closing conditions and stockholder approval. The transaction is clearly a material change of control requiring Item 1.01 disclosure.
View raw filing on EDGAR →The filing discloses a material compensatory arrangement: the Board approved a grant of 271,076 performance-based restricted stock units (PSUs) to CEO Dr. KR Sridhar on June 15, 2026, under the 2018 Equity Incentive Plan. The award is conditioned on objective revenue and margin targets through 2029 and includes a holding requirement through 2031, designed to retain the CEO and align his incentives with strategic growth priorities. This is a classic equity compensation disclosure under Item 5.02(e).
View raw filing on EDGAR →The filing's primary disclosure is the appointment of Matthew J. Koscal as a director and his concurrent assumption of the Chief Executive Officer role, effective June 15, 2026. While the section also addresses compensation updates and David Grizzle's transition from CEO to non-executive Chairman, the central event is Koscal's appointment to the Board and his succession to the CEO position, which is material to investors assessing leadership continuity and strategic direction.
View raw filing on EDGAR →Two board members—Margaret FitzPatrick and Dr. Joanne Curley—notified the Company of their decisions not to stand for re-election at the 2026 Annual Meeting. Although they will remain in office until the end of their terms, the disclosure centers on their departure from the Board, which is material to investors assessing governance and board composition at a small-cap biotech company.
View raw filing on EDGAR →The filing discloses a firm commitment underwritten offering of 592,270 shares of common stock and 296,135 warrants, with gross proceeds of approximately $5.95 million (inclusive of over-allotment exercise). This is a registered equity issuance under an effective S-3 shelf registration statement, representing a dilutive capital raise material to investors' assessment of ownership and capital structure.
View raw filing on EDGAR →The IURC issued a Rate Order on June 17, 2026 approving a Stipulation and Settlement Agreement for AES Indiana's base rate case, establishing a $1,979.7 million revenue requirement, 9.5% return on common equity, and $5.5 billion rate base effective in two phases beginning July 2026. This is a material regulatory approval affecting the subsidiary's revenue and profitability, but does not fit neatly into the specific event categories (not earnings, M&A, impairment, litigation, or other defined types). The disclosure is material to investors as it directly impacts the registrant's financial performance and regulatory standing.
View raw filing on EDGAR →The disclosure announces a Board declaration of an annual cash dividend of $0.55 per share with specific payment and record dates. While dividend declarations are routine corporate actions, this is material to shareholders as it affects their investment returns and the company's capital allocation. However, it does not fit neatly into the more specific event categories (not earnings, not executive-related, not M&A, not a restatement or going-concern issue), so "other_material" is the most appropriate classification.
View raw filing on EDGAR →Sleep Number received written notice from Nasdaq on June 16, 2026, that its common stock will be delisted from Nasdaq effective June 23, 2026, pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1. The delisting was triggered by the Company's Chapter 11 bankruptcy filing on June 12, 2026, and associated concerns about residual equity interest and ability to sustain listing compliance. This is a definitive delisting notice, not merely a risk or warning, making it a material event that fundamentally affects the trading and liquidity of the Company's securities.
View raw filing on EDGAR →This disclosure announces the effective registration and imminent completion of a spin-off separation of Midera Food Processing, Inc. from The Middleby Corporation. The filing sets the record date (June 26, 2026) and expected distribution date (July 6, 2026) for a pro rata distribution of Midera shares to Middleby shareholders. This constitutes a material change of control and disposition event that fundamentally restructures the registrant's ownership and operations, fitting the ma_activity classification for a material separation/spin-off transaction.
View raw filing on EDGAR →Magnachip entered into an At Market Issuance Sales Agreement (ATM) on June 17, 2026, authorizing the sale of up to $50 million in common stock shares through B. Riley Securities. ATM offerings are classic dilutive equity issuances that signal capital raising and potential shareholder dilution. The material nature is confirmed by the $50 million aggregate offering price and the company's stated use of proceeds for strategic growth initiatives in AI data centers and robotics.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Citizens Community Bancorp's 2026 Annual Meeting of Stockholders held on June 16, 2026. The filing reports voting outcomes for four proposals: election of three directors (Michael Conner, Francis Felber, and Nicholas Amundsen), approval of the 2026 Omnibus Incentive Plan, advisory vote on named executive officer compensation, and ratification of Crowe LLP as independent auditor. All proposals passed with substantial majorities. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →This Item 8.01 discloses the completion and post-closing mechanics of an IPO (20 million units at $10/unit generating $200M gross proceeds), a concurrent private placement ($2.1M), partial exercise of an over-allotment option (1.65M units, $16.5M), and placement of $216.5M in trust. While IPO completion is material, the disclosure is primarily administrative detail about capital raised and trust account mechanics rather than a discrete earnings release, M&A event, or other specific taxonomy event. The filing reports "as previously reported" events, suggesting this is a follow-up disclosure of already-announced transactions.
View raw filing on EDGAR →Ardelyx held its 2026 Annual Meeting of Stockholders on June 16, 2026, with shareholders voting on five proposals: election of three Class III directors (Robert Bazemore, Muna Bhanji, and Richard Rodgers), a Say-On-Pay advisory vote, a Say-On-Frequency advisory vote (annual), ratification of Ernst & Young LLP as independent auditor, and approval of the second amendment to the Amended and Restated 2014 Equity Incentive Award Plan. All proposals passed.
View raw filing on EDGAR →This Item 5.07 discloses the results of Fly-E Group's 2025 Annual Meeting of Shareholders held on June 17, 2026, including voting outcomes on three proposals: election of four directors (all approved with overwhelming support), ratification of Fortune CPA, Inc. as independent auditor (approved), and authorization for a reverse stock split at a 1-for-5 to 1-for-100 ratio at the Board's discretion (approved). The reverse stock split authorization is material to investors as it signals potential delisting risk mitigation or capital structure restructuring.
View raw filing on EDGAR →The filing discloses a material litigation development: a Supreme Court ruling on June 13, 2026 that granted in part and denied in part Fleming Intermediate Holdings LLC's motion to dismiss James River's amended complaint seeking damages for breach of contract related to a failed transaction closure. The Court allowed the Company's claims for direct damages to proceed, which represents a significant litigation milestone affecting the registrant's potential recovery and financial exposure.
View raw filing on EDGAR →The filing discloses results of a shareholder meeting held on June 16, 2026, where two proposals were voted on: (1) the Extension Amendment Proposal to extend the Business Combination Period through December 20, 2026, approved with 15,687,094 votes for and 3,284,050 against, and (2) the Auditor Ratification Proposal, approved with 16,788,360 votes for and 3,458,663 against. Item 5.07 explicitly reports submission of matters to a vote of security holders with detailed voting results, which is the defining characteristic of shareholder_vote_results. The extension of the combination period is material to investors in a SPAC, as it directly affects the timeline for completing a business combination.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of MaxCyte's 2026 annual stockholder meeting held on June 17, 2026, including voting outcomes for two proposals: election of three Class II directors (Patrick Balthrop, Cynthia Collins, and Stanley Erck) and ratification of CohnReznick LLP as the independent auditor. The tabulated vote counts for each nominee and proposal are the core disclosure, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →The filing discloses unregistered issuances of Common Stock on three dates (May 12, May 28, and June 15, 2026) totaling approximately 308,679 shares in exchange for redemptions of Series A1 and Series A Preferred Stock. The conversion prices declined sharply from $6.36 to $5.41 to $4.30 per share over the period, indicating deteriorating valuation. These are classic dilutive equity issuances that would materially affect shareholder ownership and are properly classified under Item 3.02.
View raw filing on EDGAR →The filing discloses financial and operational results for the three months and year ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, reporting quarterly and annual financial results for a public company.
View raw filing on EDGAR →Dogwood Therapeutics held its Annual Meeting of Stockholders on June 16, 2026, with shareholders voting on five proposals: election of seven directors, ratification of Forvis Mazars, LLP as auditor, amendment to the Certificate of Incorporation to increase authorized shares, Say-on-Frequency advisory vote, and Say-on-Pay advisory vote. All proposals were approved by the required vote margins.
View raw filing on EDGAR →The filing discloses unregistered sales of Class C common stock on three dates (April 15, May 14, and June 12, 2026) totaling 573,657 shares for approximately $9.6 million in aggregate consideration. Item 3.02 specifically governs unregistered equity issuances, and the company explicitly states the sales were exempt under Section 4(a)(2) and Regulation S. This is a classic dilutive issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →The Board elected Jill Livesay as a non-employee director effective July 1, 2026, and appointed her to the Audit Committee, expanding the Board from eight to nine members.
View raw filing on EDGAR →This 8-K discloses the results of Annovis Bio's 2026 Annual Meeting of Stockholders held on June 17, 2026, under Item 5.07. The filing reports voting outcomes for five proposals: election of five directors, ratification of Ernst & Young LLP as independent auditors, amendment to the 2019 Equity Incentive Plan to increase authorized shares, advisory vote on named executive officer compensation, and advisory vote on the frequency of future compensation votes. All proposals were approved. This is a routine but material shareholder vote disclosure required by Item 5.07 of Form 8-K.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Best Buy's June 12, 2026 Annual Meeting of Shareholders under Item 5.07. The filing reports voting outcomes on five matters: election of 13 directors, ratification of Deloitte & Touche LLP as independent auditor, advisory vote on executive compensation, and two shareholder proposals. All directors were elected with substantial majorities, the auditor was ratified, and executive compensation was approved, making this a material governance event that affects investor understanding of the company's board composition and shareholder sentiment.
View raw filing on EDGAR →John E. Gallagher has been appointed as Executive Vice President and Chief Financial Officer of CONMED Corporation, effective July 15, 2026, with a compensation package including a base salary of $650,000 and equity grants totaling approximately $3.8 million.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from BayCom Corp's 2026 Annual Meeting of Shareholders held on June 16, 2026. The filing reports final voting tallies for three proposals: election of nine directors, advisory vote on executive compensation, and ratification of Baker Tilly US, LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure under Item 5.07.
View raw filing on EDGAR →Cory T. Newsom was appointed as Chief Executive Officer effective upon the retirement of Curtis C. Griffith on December 31, 2026. Newsom, an internal candidate with deep institutional knowledge as President since 2019 and board member since 2008, will assume leadership while Griffith remains as Chairman.
View raw filing on EDGAR →South Plains Financial terminated a Board Representation Agreement with Henry TAW LP, a shareholder that originally owned approximately 16% and now owns less than 10% of outstanding shares. The termination reflects the Company's maturation as a public entity and shift toward a broader shareholder base.
View raw filing on EDGAR →South Plains Financial entered into a stock repurchase agreement with retiring CEO Curtis C. Griffith to repurchase 300,000 shares at fair market value, approved by the board with Griffith recused. The repurchase is a related-party transaction tied to his retirement.
View raw filing on EDGAR →The filing discloses Odyssey Therapeutics' financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the designated Item for disclosure of results of operations and financial condition.
View raw filing on EDGAR →DUOS Technologies entered into an underwritten registered direct offering of 2,000,000 shares of common stock and 3,800,000 pre-funded warrants (exercisable at $0.001) for approximately $55 million in gross proceeds. The combination of a substantial equity issuance and highly dilutive pre-funded warrants represents a material capital raise that will significantly dilute existing shareholders.
View raw filing on EDGAR →QVC Inc. and its affiliates filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas on April 16, 2026. Although this Item 7.01 disclosure focuses on the filing of monthly operating reports required by the Bankruptcy Code, it explicitly references and incorporates the prior 8-K filing disclosing the Chapter 11 Cases themselves. The bankruptcy filing is the material event that triggered this disclosure and is terminal in nature, representing the most significant financial distress signal.
View raw filing on EDGAR →Fiserv entered into an Underwriting Agreement on June 16, 2026, to issue €1 billion in senior notes (€500M due 2030 at 3.750% and €500M due 2034 at 4.250%) in a public offering expected to close June 23, 2026. While this is a debt issuance rather than a traditional M&A transaction, Item 1.01 ("Entry into a Material Definitive Agreement") captures material financing arrangements. The €1 billion aggregate principal amount and the formal underwriting structure with major investment banks (Citigroup, J.P. Morgan, TD, Wells Fargo) indicate materiality to investors assessing the company's capital structure and liquidity.
View raw filing on EDGAR →Plains GP Holdings terminated two material credit facilities (the Existing Revolving Credit Agreement and the Hedged Inventory Facility) and closed a new Revolving Credit Agreement, representing a routine refinancing of its credit arrangements.
View raw filing on EDGAR →The filing discloses that QVC Group, Inc. and certain affiliates filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas on April 16, 2026. While this 8-K is technically filed under Item 7.01 (Regulation FD Disclosure) to furnish monthly operating reports required by the Bankruptcy Code, the core material event is the Chapter 11 bankruptcy filing itself, which was previously disclosed on April 16, 2026. This is a terminal signal event of the highest materiality.
View raw filing on EDGAR →The filing discloses the appointment of Michael Feigin to CitroTech's board of directors on June 17, 2026, effective immediately, to fill one of two vacancies created by director resignations. While the section also reports the resignations of Theodore Ralston and Jeffery Pomerantz, the principal action disclosed is the appointment of a new director with detailed biographical information and committee assignments, making exec_appointment the most salient event. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →HEICO entered into a fourth amendment to its revolving credit facility on June 11, 2026, which increased capacity from $2.0 billion to $2.2 billion, extended maturity to June 11, 2031, and modified rating-based pricing terms. While this is a material refinancing and credit facility modification that affects the company's financial flexibility and debt structure, it is not a traditional M&A transaction. However, Item 1.01 is being used here, which typically covers material definitive agreements including significant credit facility amendments. The materiality is clear given the $200 million capacity increase and five-year maturity extension, but the event is more accurately characterized as a material credit facility amendment rather than M&A activity proper.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from Sabra Health Care REIT's annual meeting of stockholders held on June 17, 2026. The filing presents detailed voting tallies for three matters: election of seven directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. Shareholder vote results are material to investors as they confirm governance composition and audit oversight for the fiscal year.
View raw filing on EDGAR →